STOCK TITAN

Beta Bionics officer plans $541K stock sale

A Beta Bionics officer notified intent to sell 28,119 BBNX shares under Rule 144, mainly from option exercises and vested RSUs.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) officer Mark Hopman has filed a notice to sell 28,119 shares of common stock under Rule 144, with an aggregate market value of $540,728.37, when Beta Bionics had 44,989,688 shares outstanding.

The planned sales relate to 25,265 shares acquired through the exercise of stock options on September 16, 2026, and 2,854 shares acquired upon vesting of restricted stock units on June 1, 2025.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 28,119 shares Common stock listed for sale through Morgan Stanley Smith Barney LLC
Aggregate market value of planned sale $540,728.37 Value of 28,119 Beta Bionics common shares listed for sale
Shares outstanding 44,989,688 shares Beta Bionics common stock outstanding when the notice was filed
Shares from stock option exercise 25,265 shares Common shares to be sold acquired by option exercise on September 16, 2026
Shares from RSU vesting 2,854 shares Common shares to be sold acquired from restricted stock unit vesting on June 1, 2025
Recent 10b5-1 sale (largest) 36,870 shares for $680,723.44 Common shares sold on September 9, 2026 under a 10b5-1 plan
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
restricted stock units financial
"The securities to be sold were acquired upon the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Exercise of Stock Options financial
"Common | 09/16/2026 | Exercise of Stock Options | Issuer"
10b5-1 Sales regulatory
"10b5-1 Sales for MARK AUGUST HOPMAN 11 Hughes Irvine CA 92618"
10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Beta Bionics (BBNX) insider Mark Hopman planning to sell under Rule 144?

Mark Hopman filed to sell 28,119 shares of Beta Bionics common stock under Rule 144, with an aggregate market value of $540,728.37, through Morgan Stanley Smith Barney LLC on NASDAQ.

How were the BBNX shares to be sold by Mark Hopman acquired?

The notice states 25,265 shares were acquired via exercise of stock options on September 16, 2026, and 2,854 shares were acquired upon vesting of restricted stock units on June 1, 2025.

What recent BBNX share sales has Mark Hopman reported in the last 3 months?

Reported past 3‑month sales include 36,870 shares for $680,723.44 on September 9, 2026, 5,327 shares for $101,815.48 on September 2, 2026, 775 shares for $12,028.00 on September 14, 2026, and 1,258 shares for $18,880.44 on June 24, 2026.

What portion of Beta Bionics (BBNX) share capital does the planned Rule 144 sale represent?

The notice lists 28,119 shares to be sold when 44,989,688 shares of Beta Bionics common stock were outstanding, indicating the sale involves a small fraction of the company’s outstanding shares.

Were any of Mark Hopman’s recent BBNX sales made under a 10b5-1 trading plan?

Yes. The sales of 775 shares on September 14, 2026 and 36,870 shares on September 9, 2026 are described as 10b5-1 sales for Mark August Hopman.

What types of Beta Bionics (BBNX) equity awards are involved in Mark Hopman’s planned sales?

The planned sales involve shares acquired from stock option exercises and from the vesting of restricted stock units during the period from June 1, 2025 through June 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading